A major structural retroviral protein, capsid protein (CA), is able to oligomerize into two different hexameric lattices, which makes this protein a key component for both the early and late stages of HIV-1 replication. During the late stage, the CA protein, as part of the Gag polyprotein precursor, facilitates protein-protein interactions that lead to the assembly of immature particles. Following protease activation and Gag polyprotein processing, CA also drives the assembly of the mature viral core. In the early stage of infection, the role of the CA protein is distinct. It controls the disassembly of the mature CA hexameric lattice i.e., uncoating, which is critical for the reverse transcription of the single-stranded RNA genome into double stranded DNA. These properties make CA a very attractive target for small molecule functioning as inhibitors of HIV-1 particle assembly and/or disassembly. Of these, inhibitors containing the PF74 scaffold have been extensively studied. In this study, we reported a series of modifications of the PF74 molecule and its characterization through a combination of biochemical and structural approaches. Our data supported the hypothesis that PF74 stabilizes the mature HIV-1 CA hexameric lattice. We identified derivatives with a higher in vitro stabilization activity in comparison to the original PF74 molecule.

Department of Biochemistry and Microbiology University of Chemistry and Technology 166 28 Prague Czech Republic

Department of Biotechnology University of Chemistry and Technology 166 28 Prague Czech Republic

Department of Chemistry of Natural Compounds University of Chemistry and Technology 166 28 Prague Czech Republic

NMR Laboratory University of Chemistry and Technology 166 28 Prague Czech Republic

Zobrazit více v PubMed

Qu K., Glass B., Dolezal M., Schur F.K.M., Murciano B., Rein A., Rumlova M., Ruml T., Krausslich H.G., Briggs J.A.G. Structure and architecture of immature and mature murine leukemia virus capsids. Proc. Natl. Acad. Sci. USA. 2018;115:E11751–E11760. doi: 10.1073/pnas.1811580115. PubMed DOI PMC

Schur F.K., Hagen W.J., Rumlova M., Ruml T., Muller B., Krausslich H.G., Briggs J.A. Structure of the immature HIV-1 capsid in intact virus particles at 8.8 A resolution. Nature. 2015;517:505–508. doi: 10.1038/nature13838. PubMed DOI

Schur F.K., Dick R.A., Hagen W.J., Vogt V.M., Briggs J.A. The Structure of Immature Virus-Like Rous Sarcoma Virus Gag Particles Reveals a Structural Role for the p10 Domain in Assembly. J. Virol. 2015;89:10294–10302. doi: 10.1128/JVI.01502-15. PubMed DOI PMC

Bharat T.A.M., Davey N.E., Ulbrich P., Riches J.D., de Marco A., Rumlová M., Sachse C., Ruml T., Briggs J.A.G. Structure of the immature retroviral capsid at 8 Å resolution by cryo-electron microscopy. Nature. 2012;487:385–389. doi: 10.1038/nature11169. PubMed DOI

Briggs J.A.G., Riches J.D., Glass B., Bartonova V., Zanetti G., Kräusslich H.G. Structure and assembly of immature HIV. Proc. Natl. Acad. Sci. USA. 2009;106:11090–11095. doi: 10.1073/pnas.0903535106. PubMed DOI PMC

Mattei S., Glass B., Hagen W.J., Krausslich H.G., Briggs J.A. The structure and flexibility of conical HIV-1 capsids determined within intact virions. Science. 2016;354:1434–1437. doi: 10.1126/science.aah4972. PubMed DOI

Cao S., Maldonado J.O., Grigsby I.F., Mansky L.M., Zhang W. Analysis of human T-cell leukemia virus type 1 particles by using cryo-electron tomography. J. Virol. 2015;89:2430–2435. doi: 10.1128/JVI.02358-14. PubMed DOI PMC

Zhao G., Perilla J.R., Yufenyuy E.L., Meng X., Chen B., Ning J., Ahn J., Gronenborn A.M., Schulten K., Aiken C., et al. Mature HIV-1 capsid structure by cryo-electron microscopy and all-atom molecular dynamics. Nature. 2013;497:643–646. doi: 10.1038/nature12162. PubMed DOI PMC

Butan C., Winkler D.C., Heymann J.B., Craven R.C., Steven A.C. RSV Capsid Polymorphism Correlates with Polymerization Efficiency and Envelope Glycoprotein Content: Implications that Nucleation Controls Morphogenesis. J. Mol. Biol. 2008;376:1168–1181. doi: 10.1016/j.jmb.2007.12.003. PubMed DOI PMC

Ganser-Pornillos B.K., von Schwedler U.K., Stray K.M., Aiken C., Sundquist W.I. Assembly properties of the human immunodeficiency virus type 1 CA protein. J. Virol. 2004;78:2545–2552. doi: 10.1128/JVI.78.5.2545-2552.2004. PubMed DOI PMC

Ganser-Pornillos B.K., Yeager M., Sundquist W.I. The structural biology of HIV assembly. Curr.Opin.Struct. Biol. 2008;18:203–217. doi: 10.1016/j.sbi.2008.02.001. PubMed DOI PMC

Zhang W., Cao S., Martin J.L., Mueller J.D., Mansky L.M. Morphology and ultrastructure of retrovirus particles. AIMS Biophys. 2015;2:343–369. doi: 10.3934/biophy.2015.3.343. PubMed DOI PMC

Campbell E.M., Hope T.J. HIV-1 capsid: The multifaceted key player in HIV-1 infection. Nat. Rev. Microbiol. 2015;13:471–483. doi: 10.1038/nrmicro3503. PubMed DOI PMC

Rasaiyaah J., Tan C.P., Fletcher A.J., Price A.J., Blondeau C., Hilditch L., Jacques D.A., Selwood D.L., James L.C., Noursadeghi M., et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature. 2013;503:402. doi: 10.1038/nature12769. PubMed DOI PMC

Francis A.C., Melikyan G.B. Single HIV-1 Imaging Reveals Progression of Infection through CA-Dependent Steps of Docking at the Nuclear Pore, Uncoating, and Nuclear Transport. Cell Host Microbe. 2018;23:536–548.e6. doi: 10.1016/j.chom.2018.03.009. PubMed DOI PMC

Burdick R.C., Delviks-Frankenberry K.A., Chen J., Janaka S.K., Sastri J., Hu W.S., Pathak V.K. Dynamics and regulation of nuclear import and nuclear movements of HIV-1 complexes. PLoS Pathog. 2017;13:e1006570. doi: 10.1371/journal.ppat.1006570. PubMed DOI PMC

Matreyek K.A., Engelman A. The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J. Virol. 2011;85:7818–7827. doi: 10.1128/JVI.00325-11. PubMed DOI PMC

Hilditch L., Towers G.J. A model for cofactor use during HIV-1 reverse transcription and nuclear entry. Curr. Opin. Virol. 2014;4:32–36. doi: 10.1016/j.coviro.2013.11.003. PubMed DOI PMC

Hulme A.E., Perez O., Hope T.J. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc. Natl. Acad. Sci. USA. 2011;108:9975–9980. doi: 10.1073/pnas.1014522108. PubMed DOI PMC

Mamede J.I., Cianci G.C., Anderson M.R., Hope T.J. Early cytoplasmic uncoating is associated with infectivity of HIV-1. Proc. Natl. Acad. Sci. USA. 2017;114:E7169–E7178. doi: 10.1073/pnas.1706245114. PubMed DOI PMC

Lukic Z., Dharan A., Fricke T., Diaz-Griffero F., Campbell E.M. HIV-1 uncoating is facilitated by dynein and kinesin 1. J. Virol. 2014;88:13613–13625. doi: 10.1128/JVI.02219-14. PubMed DOI PMC

Price A.J., Jacques D.A., McEwan W.A., Fletcher A.J., Essig S., Chin J.W., Halambage U.D., Aiken C., James L.C. Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly. PLoS Pathog. 2014;10:e1004459. doi: 10.1371/journal.ppat.1004459. PubMed DOI PMC

Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., Sodroski J. The cytoplasmic body component TRIM5 alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004;427:848–853. doi: 10.1038/nature02343. PubMed DOI

Matreyek K.A., Engelman A. Viral and cellular requirements for the nuclear entry of retroviral preintegration nucleoprotein complexes. Viruses. 2013;5:2483–2511. doi: 10.3390/v5102483. PubMed DOI PMC

Xu H., Franks T., Gibson G., Huber K., Rahm N., Strambio De Castillia C., Luban J., Aiken C., Watkins S., Sluis-Cremer N., et al. Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology. 2013;10:70. doi: 10.1186/1742-4690-10-70. PubMed DOI PMC

Blanco-Rodriguez G., Gazi A., Monel B., Frabetti S., Scoca V., Mueller F., Schwartz O., Krijnse-Locker J., Charneau P., Di Nunzio F. Remodeling of the core leads HIV-1 pre-integration complex in the nucleus of human lymphocytes. J. Virol. 2020 doi: 10.1128/JVI.00135-20. PubMed DOI PMC

Yang Y., Fricke T., Diaz-Griffero F. Inhibition of reverse transcriptase activity increases stability of the HIV-1 core. J. Virol. 2013;87:683–687. doi: 10.1128/JVI.01228-12. PubMed DOI PMC

Cosnefroy O., Murray P.J., Bishop K.N. HIV-1 capsid uncoating initiates after the first strand transfer of reverse transcription. Retrovirology. 2016;13:58. doi: 10.1186/s12977-016-0292-7. PubMed DOI PMC

Franke E.K., Yuan H.E., Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature. 1994;372:359–362. doi: 10.1038/372359a0. PubMed DOI

Brass A.L., Dykxhoorn D.M., Benita Y., Yan N., Engelman A., Xavier R.J., Lieberman J., Elledge S.J. Identification of host proteins required for HIV infection through a functional genomic screen. Science. 2008;319:921–926. doi: 10.1126/science.1152725. PubMed DOI

Krishnan L., Matreyek K.A., Oztop I., Lee K., Tipper C.H., Li X., Dar M.J., Kewalramani V.N., Engelman A. The requirement for cellular transportin 3 (TNPO3 or TRN-SR2) during infection maps to human immunodeficiency virus type 1 capsid and not integrase. J. Virol. 2010;84:397–406. doi: 10.1128/JVI.01899-09. PubMed DOI PMC

Lee K., Ambrose Z., Martin T.D., Oztop I., Mulky A., Julias J.G., Vandegraaff N., Baumann J.G., Wang R., Yuen W., et al. Flexible Use of Nuclear Import Pathways by HIV-1. Cell Host Microbe. 2010;7:221–233. doi: 10.1016/j.chom.2010.02.007. PubMed DOI PMC

Price A.J., Fletcher A.J., Schaller T., Elliott T., Lee K., KewalRamani V.N., Chin J.W., Towers G.J., James L.C. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog. 2012;8:e1002896. doi: 10.1371/journal.ppat.1002896. PubMed DOI PMC

Bushman F.D., Malani N., Fernandes J., D’Orso I., Cagney G., Diamond T.L., Zhou H., Hazuda D.J., Espeseth A.S., König R., et al. Host Cell Factors in HIV Replication: Meta-Analysis of Genome-Wide Studies. PLoS Pathog. 2009;5:e1000437. doi: 10.1371/journal.ppat.1000437. PubMed DOI PMC

Konig R., Zhou Y., Elleder D., Diamond T.L., Bonamy G.M., Irelan J.T., Chiang C.Y., Tu B.P., De Jesus P.D., Lilley C.E., et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell. 2008;135:49–60. doi: 10.1016/j.cell.2008.07.032. PubMed DOI PMC

Dick R.A., Mallery D.L., Vogt V.M., James L.C. IP6 Regulation of HIV Capsid Assembly, Stability, and Uncoating. Viruses. 2018;10:640. doi: 10.3390/v10110640. PubMed DOI PMC

Dick R.A., Zadrozny K.K., Xu C., Schur F.K.M., Lyddon T.D., Ricana C.L., Wagner J.M., Perilla J.R., Ganser-Pornillos B.K., Johnson M.C., et al. Inositol phosphates are assembly co-factors for HIV-1. Nature. 2018;560:509–512. doi: 10.1038/s41586-018-0396-4. PubMed DOI PMC

Mallery D.L., Marquez C.L., McEwan W.A., Dickson C.F., Jacques D.A., Anandapadamanaban M., Bichel K., Towers G.J., Saiardi A., Bocking T., et al. IP6 is an HIV pocket factor that prevents capsid collapse and promotes DNA synthesis. Elife. 2018;7:e35335. doi: 10.7554/eLife.35335. PubMed DOI PMC

Rihn S.J., Wilson S.J., Loman N.J., Alim M., Bakker S.E., Bhella D., Gifford R.J., Rixon F.J., Bieniasz P.D. Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog. 2013;9:e1003461. doi: 10.1371/journal.ppat.1003461. PubMed DOI PMC

Forshey B.M., von Schwedler U., Sundquist W.I., Aiken C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 2002;76:5667–5677. doi: 10.1128/JVI.76.11.5667-5677.2002. PubMed DOI PMC

Novikova M., Zhang Y., Freed E.O., Peng K. Multiple Roles of HIV-1 Capsid during the Virus Replication Cycle. Virol. Sin. 2019;34:119–134. doi: 10.1007/s12250-019-00095-3. PubMed DOI PMC

Thenin-Houssier S., Valente S.T. HIV-1 Capsid Inhibitors as Antiretroviral Agents. Curr. HIV Res. 2016;14:270–282. doi: 10.2174/1570162X14999160224103555. PubMed DOI PMC

Rumlova M., Ruml T. In vitro methods for testing antiviral drugs. Biotechnol. Adv. 2017;36:557–576. doi: 10.1016/j.biotechadv.2017.12.016. PubMed DOI PMC

Carnes S.K., Sheehan J.H., Aiken C. Inhibitors of the HIV-1 capsid, a target of opportunity. Curr. Opin. HIV AIDS. 2018;13:359–365. doi: 10.1097/COH.0000000000000472. PubMed DOI PMC

Yant S.R., Mulato A., Hansen D., Tse W.C., Niedziela-Majka A., Zhang J.R., Stepan G.J., Jin D., Wong M.H., Perreira J.M., et al. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. Nat. Med. 2019;25:1377–1384. doi: 10.1038/s41591-019-0560-x. PubMed DOI PMC

McArthur C., Gallazzi F., Quinn T.P., Singh K. HIV Capsid Inhibitors Beyond PF74. Diseases. 2019;7:56. doi: 10.3390/diseases7040056. PubMed DOI PMC

Blair W.S., Pickford C., Irving S.L., Brown D.G., Anderson M., Bazin R., Cao J., Ciaramella G., Isaacson J., Jackson L., et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 2010;6:e1001220. doi: 10.1371/journal.ppat.1001220. PubMed DOI PMC

Saito A., Ferhadian D., Sowd G.A., Serrao E., Shi J., Halambage U.D., Teng S., Soto J., Siddiqui M.A., Engelman A.N., et al. Roles of Capsid-Interacting Host Factors in Multimodal Inhibition of HIV-1 by PF74. J. Virol. 2016;90:5808–5823. doi: 10.1128/JVI.03116-15. PubMed DOI PMC

Shi J., Zhou J., Shah V.B., Aiken C., Whitby K. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J. Virol. 2011;85:542–549. doi: 10.1128/JVI.01406-10. PubMed DOI PMC

Zhou J., Price A.J., Halambage U.D., James L.C., Aiken C. HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry. J. Virol. 2015;89:9068–9079. doi: 10.1128/JVI.00340-15. PubMed DOI PMC

Bhattacharya A., Alam S.L., Fricke T., Zadrozny K., Sedzicki J., Taylor A.B., Demeler B., Pornillos O., Ganser-Pornillos B.K., Diaz-Griffero F., et al. Structural basis of HIV-1 capsid recognition by PF74 and CPSF6. Proc. Natl. Acad. Sci. USA. 2014;111:18625–18630. doi: 10.1073/pnas.1419945112. PubMed DOI PMC

Rankovic S., Ramalho R., Aiken C., Rousso I. PF74 Reinforces the HIV-1 Capsid To Impair Reverse Transcription-Induced Uncoating. J. Virol. 2018;92 doi: 10.1128/JVI.00845-18. PubMed DOI PMC

Fricke T., Buffone C., Opp S., Valle-Casuso J., Diaz-Griffero F. BI-2 destabilizes HIV-1 cores during infection and Prevents Binding of CPSF6 to the HIV-1 Capsid. Retrovirology. 2014;11:120. doi: 10.1186/s12977-014-0120-x. PubMed DOI PMC

Buffone C., Martinez-Lopez A., Fricke T., Opp S., Severgnini M., Cifola I., Petiti L., Frabetti S., Skorupka K., Zadrozny K.K., et al. Nup153 Unlocks the Nuclear Pore Complex for HIV-1 Nuclear Translocation in Nondividing Cells. J. Virol. 2018;92 doi: 10.1128/JVI.00648-18. PubMed DOI PMC

Xu J.P., Francis A.C., Meuser M.E., Mankowski M., Ptak R.G., Rashad A.A., Melikyan G.B., Cocklin S. Exploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action. J. Drug Des. Res. 2018;5:1070. PubMed PMC

Wu G., Zalloum W.A., Meuser M.E., Jing L., Kang D., Chen C.H., Tian Y., Zhang F., Cocklin S., Lee K.H., et al. Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library. Eur. J. Med. Chem. 2018;158:478–492. doi: 10.1016/j.ejmech.2018.09.029. PubMed DOI PMC

Dostalkova A., Hadravova R., Kaufman F., Krizova I., Skach K., Flegel M., Hrabal R., Ruml T., Rumlova M. A simple, high-throughput stabilization assay to test HIV-1 uncoating inhibitors. Sci. Rep. 2019;9:17076. doi: 10.1038/s41598-019-53483-w. PubMed DOI PMC

Hadravova R., Rumlova M., Ruml T. FAITH—Fast Assembly Inhibitor Test for HIV. Virology. 2015;486:78–87. doi: 10.1016/j.virol.2015.08.029. PubMed DOI

Sticht J., Humbert M., Findlow S., Bodem J., Muller B., Dietrich U., Werner J., Krausslich H.G. A peptide inhibitor of HIV-1 assembly in vitro. Nat. Struct. Mol. Biol. 2005;12:671–677. doi: 10.1038/nsmb964. PubMed DOI

Hulme A.E., Hope T.J. The cyclosporin A washout assay to detect HIV-1 uncoating in infected cells. Methods Mol. Biol. 2014;1087:37–46. PubMed PMC

Ulbrich P., Haubova S., Nermut M.V., Hunter E., Rumlova M., Ruml T. Distinct roles for nucleic acid in in vitro assembly of purified Mason-Pfizer monkey virus CANC proteins. J. Virol. 2006;80:7089–7099. doi: 10.1128/JVI.02694-05. PubMed DOI PMC

Rumlova M., Krizova I., Zelenka J., Weber J., Ruml T. Does BCA3 Play a Role in the HIV-1 Replication Cycle? Viruses. 2018;10:212. doi: 10.3390/v10040212. PubMed DOI PMC

Campbell S., Vogt V.M. Self-Assembly In-Vitro of Purified Ca-Nc Proteins from Rous-Sarcoma Virus and Human-Immunodeficiency-Virus Type-1. J. Virol. 1995;69:6487–6497. doi: 10.1128/JVI.69.10.6487-6497.1995. PubMed DOI PMC

Rumlova M., Ruml T., Pohl J., Pichova I. Specific in vitro cleavage of Mason-Pfizer monkey virus capsid protein: Evidence for a potential role of retroviral protease in early stages of infection. Virology. 2003;310:310–318. doi: 10.1016/S0042-6822(03)00128-4. PubMed DOI

Dostalkova A., Kaufman F., Krizova I., Kultova A., Strohalmova K., Hadravova R., Ruml T., Rumlova M. Mutations in the basic region of the Mason-Pfizer monkey virus nucleocapsid protein affect reverse transcription, gRNA packaging and the site of viral assembly. J. Virol. 2018 doi: 10.1128/JVI.00106-18. PubMed DOI PMC

Krizova I., Hadravova R., Stokrova J., Gunterova J., Dolezal M., Ruml T., Rumlova M., Pichova I. The G-patch domain of Mason-Pfizer monkey virus is a part of reverse transcriptase. J. Virol. 2012;86:1988–1998. doi: 10.1128/JVI.06638-11. PubMed DOI PMC

Strohalmova-Bohmova K., Spiwok V., Lepsik M., Hadravova R., Krizova I., Ulbrich P., Pichova I., Bednarova L., Ruml T., Rumlova M. Role of Mason-Pfizer monkey virus CA-NC spacer peptide-like domain in assembly of immature particles. J. Virol. 2014;88:14148–14160. doi: 10.1128/JVI.02286-14. PubMed DOI PMC

Keprova A., Korinkova L., Krizova I., Hadravova R., Kaufman F., Pichova I., Ruml T., Rumlova M. Various AKIP1 expression levels affect its subcellular localization but have no effect on NF-kappaB activation. Physiol. Res. 2019;68:431–443. doi: 10.33549/physiolres.933961. PubMed DOI

Kirakci K., Demel J., Hynek J., Zelenka J., Rumlova M., Ruml T., Lang K. Phosphinate Apical Ligands: A Route to a Water-Stable Octahedral Molybdenum Cluster Complex. Inorg. Chem. 2019;58:16546–16552. doi: 10.1021/acs.inorgchem.9b02569. PubMed DOI

Kirakci K., Zelenka J., Rumlova M., Cvacka J., Ruml T., Lang K. Cationic octahedral molybdenum cluster complexes functionalized with mitochondria-targeting ligands: Photodynamic anticancer and antibacterial activities. Biomater. Sci. 2019;7:1386–1392. doi: 10.1039/C8BM01564C. PubMed DOI

Rumlova M., Krizova I., Keprova A., Hadravova R., Dolezal M., Strohalmova K., Pichova I., Hajek M., Ruml T. HIV-1 protease-induced apoptosis. Retrovirology. 2014;11:37. doi: 10.1186/1742-4690-11-37. PubMed DOI PMC

Preparation and Biological Activity of Lignin-Silver Hybrid Nanoparticles

Fullerene Derivatives Prevent Packaging of Viral Genomic RNA into HIV-1 Particles by Binding Nucleocapsid Protein